TPBG
TWST icon

Turning Point Benefit Group’s Twist Bioscience TWST Stock Holding History

Turning Point Benefit Group’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$31 – 736
2025
Q4 		$31 Hold
1
– – ﹤0.01% 838
2025
Q3 		$29 Buy
+1
New +$30 ﹤0.01% 751

Other funds holding TWST

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Turning Point Benefit Group's TWST Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Twist Bioscience (TWST) in Q1 2026, closing a stake of 1 share — an estimated $31 sold.

Turning Point Benefit Group first reported a position in TWST in Q3 2025 and held it in 2 quarters. The position peaked at $31 in Q4 2025. 280 funds tracked by Wall St. Rank hold TWST as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Twist Bioscience position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 1 Twist Bioscience share in Q1 2026, an estimated $31.
  • Turning Point Benefit Group first reported a position in Twist Bioscience in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Twist Bioscience position peaked at $31 in Q4 2025.
  • 280 funds tracked by Wall St. Rank held Twist Bioscience as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.